New Purpose-Built Facility Strengthens BioAgilytix’s Global Capabilities in Bioanalytical Sciences, Supporting Healthcare Advances 

Melbourne, Australia – 360biolabs, a BioAgilytix Company, proudly announces the grand opening of a state-of-the-art bioanalytical laboratory in Melbourne, Australia. 360biolabs is Australia’s most comprehensive bioanalytical laboratory, offering a complete suite of services to meet all your bioanalytical needs. Services include LC-MS/MS, Molecular, Biomarker, Flow cytometry, Large molecule PK and immunogenicity, Virology, and Central Lab Services, all conducted in a quality-assured environment (GLP, GCP, GCLP, ISO / IEC 17025).  

This newly established, purpose-built campus offers comprehensive bioanalytical services designed to support pharmaceutical and biotech clients on a global scale. Australia is one of the leading destinations for early-phase clinical trials, providing an efficient and pragmatic regulatory environment, internationally recognized quality systems, and competitive R&D tax incentives. This expansion represents a significant milestone in BioAgilytix’s ongoing global expansion, growth, and commitment to enhancing assay development and advancing medical innovation. 

360biolabs’ grand opening event was filled with excitement and a strong sense of community, celebrating this new chapter in BioAgilytix’s global journey, bringing together esteemed Australian biotech partners, stakeholders from across the life sciences industry and its representative bodies “We are thrilled to expand our footprint in Melbourne, a city known for its vibrant biotech community,” said Davide Molho, CEO of BioAgilytix. “This new facility not only reflects our continuous growth but also our dedication to leveraging top-tier talent and cutting-edge technology to better serve our global partners and drive critical clinical trials forward.” 

Alistair Draffan, President 360biolabs, emphasized the importance of teamwork and trust, underscoring the company’s strong relationships with industry partners and the dedication of its nearly 150 experts in the region. “Our success is built on the trust our partners have in our capabilities and our shared commitment to advancing science. This purpose-built, world-class facility comprises 3,000 sqm of laboratory and office space ensuring that we can continue to meet the expectations of our clients who have trusted us to provide expert bioanalytical services for their innovative medicines.” Alistair stated. 

John Berger MP, representing the Minister for Health Education and Research, and Dr. Amanda Caples, Victoria’s Lead Scientist, both praised the new facility’s potential to bolster Victoria’s standing as a leader in biotech research and innovation. 

As BioAgilytix continues its trajectory of growth, with recent expansions in: Durham, NC, San Diego, CA, Hamburg, Germany and Melbourne’s new laboratory.  Under the leadership of new Chief Growth Officer Ed Amat and CEO Davide Molho, the global team will play a pivotal role in supporting global clinical trials and fostering scientific advancements that benefit healthcare worldwide. 

For more information about 360biolabs and its services, please visit 360biolabs.com or visit bioagilytix.com. 

About BioAgilytix

As a leading global bioanalytical laboratory, BioAgilytix is the trusted partner for bioanalytical services from discovery through every phase of the drug development process. Serving established and emerging pharmaceutical and biotechnology organizations, the company provides diagnostic, pharmacokinetic (PK), immunogenicity, biomarkers, and cell-based assay services from laboratories in Durham, North Carolina; Boston, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia; and Hamburg, Germany. For more information, please visit www.bioagilytix.com.

For more information, please contact:

Noelle Brawner
Communications Manager
BioAgilytix Labs, LLC
Noelle.brawner@bioagilytix.com